These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17327374)

  • 41. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
    Lauricella M; Emanuele S; D'Anneo A; Calvaruso G; Vassallo B; Carlisi D; Portanova P; Vento R; Tesoriere G
    Apoptosis; 2006 Apr; 11(4):607-25. PubMed ID: 16528474
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.
    Emanuele S; Lauricella M; Carlisi D; Vassallo B; D'Anneo A; Di Fazio P; Vento R; Tesoriere G
    Apoptosis; 2007 Jul; 12(7):1327-38. PubMed ID: 17351739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proteasome inhibition induces hepatic stellate cell apoptosis.
    Anan A; Baskin-Bey ES; Bronk SF; Werneburg NW; Shah VH; Gores GJ
    Hepatology; 2006 Feb; 43(2):335-44. PubMed ID: 16440346
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Melatonin as a proteasome inhibitor. Is there any clinical evidence?
    Vriend J; Reiter RJ
    Life Sci; 2014 Oct; 115(1-2):8-14. PubMed ID: 25219883
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis.
    Koschny R; Holland H; Sykora J; Erdal H; Krupp W; Bauer M; Bockmuehl U; Ahnert P; Meixensberger J; Stremmel W; Walczak H; Ganten TM
    J Neurooncol; 2010 Apr; 97(2):171-85. PubMed ID: 19768634
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.
    Conticello C; Adamo L; Vicari L; Giuffrida R; Iannolo G; Anastasi G; Caruso L; Moschetti G; Cupri A; Palumbo GA; Gulisano M; De Maria R; Giustolisi R; Di Raimondo F
    Acta Haematol; 2008; 120(1):19-30. PubMed ID: 18716397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).
    Chopin V; Slomianny C; Hondermarck H; Le Bourhis X
    Exp Cell Res; 2004 Aug; 298(2):560-73. PubMed ID: 15265702
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL.
    Lu G; Punj V; Chaudhary PM
    Cancer Biol Ther; 2008 Apr; 7(4):603-8. PubMed ID: 18223318
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
    Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
    Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
    [TBL] [Abstract][Full Text] [Related]  

  • 50. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.
    Seol DW
    Biochem Biophys Res Commun; 2011 Dec; 416(1-2):222-5. PubMed ID: 22120628
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
    Bullenkamp J; Raulf N; Ayaz B; Walczak H; Kulms D; Odell E; Thavaraj S; Tavassoli M
    Cell Death Dis; 2014 Oct; 5(10):e1489. PubMed ID: 25341043
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The flavonolignan silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells.
    Kauntz H; Bousserouel S; Gossé F; Raul F
    Apoptosis; 2012 Aug; 17(8):797-809. PubMed ID: 22555452
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib.
    Wahl K; Siegemund M; Lehner F; Vondran F; Nüssler A; Länger F; Krech T; Kontermann R; Manns MP; Schulze-Osthoff K; Pfizenmaier K; Bantel H
    Hepatology; 2013 Feb; 57(2):625-36. PubMed ID: 22991197
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
    Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
    Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
    Canestraro M; Galimberti S; Savli H; Palumbo GA; Tibullo D; Nagy B; Guerrini F; Piaggi S; Cine N; Metelli MR; Petrini M
    Cancer Genet Cytogenet; 2010 Jun; 199(2):110-20. PubMed ID: 20471514
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
    Luster TA; Carrell JA; McCormick K; Sun D; Humphreys R
    Mol Cancer Ther; 2009 Feb; 8(2):292-302. PubMed ID: 19174554
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
    Cha HY; Lee BS; Chang JW; Park JK; Han JH; Kim YS; Shin YS; Byeon HK; Kim CH
    Cancer Lett; 2016 Mar; 372(1):65-74. PubMed ID: 26721202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
    Shanker A; Brooks AD; Tristan CA; Wine JW; Elliott PJ; Yagita H; Takeda K; Smyth MJ; Murphy WJ; Sayers TJ
    J Natl Cancer Inst; 2008 May; 100(9):649-62. PubMed ID: 18445820
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex.
    Koschny R; Boehm C; Sprick MR; Haas TL; Holland H; Xu LX; Krupp W; Mueller WC; Bauer M; Koschny T; Keller M; Sinn P; Meixensberger J; Walczak H; Ganten TM
    J Neuropathol Exp Neurol; 2014 Nov; 73(11):1034-46. PubMed ID: 25289891
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link.
    Fulda S
    Oncotarget; 2011 May; 2(5):418-21. PubMed ID: 21789791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.